Tirpezatide 40mg Pen – Alluvi

The Alluvi Tirzepatide 40mg Injection Pen is a lower-content pre-filled pen for users starting Tirzepatide or running shorter treatment periods. It provides the same pharmaceutical-grade Tirzepatide as the 70mg pen kit in a smaller total volume. The 40mg pen is ideal for users in the dose-escalation phase (weeks 1-8) where weekly doses are 2.5-5mg, providing approximately 8-16 weeks of treatment at initial titration doses.

Dosage Protocol

• Week 1-4: 2.5mg once weekly
• Week 5-8: 5mg once weekly
• Pen yield: approximately 8-16 weeks depending on dose
• Injection: subcutaneous, abdomen or thigh

Why Start with the 40mg Pen

First-time Tirzepatide users spend 8-12 weeks in the dose-escalation phase at 2.5-5mg/week. The 40mg pen covers this entire titration period at a lower upfront cost than the 70mg kit. Once you confirm tolerance and decide to continue at higher maintenance doses (10-15mg/week), the 70mg pen becomes more cost-effective.

Key Facts

• Total content: 40mg Tirzepatide
• Format: pre-filled injection pen
• Class: GLP-1/GIP dual receptor agonist
• Storage: refrigerate
• No testosterone suppression. No PCT required

Browse our full weight loss range including Semaglutide and Retatrutide.